Ocugen (Ocugen) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Days Payable?

Ocugen's average Accounts Payable for the three months ended in Dec. 2023 was $3.05 Mil. Ocugen's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Ocugen's Days Payable or its related term are showing as below:

OCGN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.95
* Ranked among companies with meaningful Days Payable only.

Ocugen's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Ocugen Days Payable Historical Data

The historical data trend for Ocugen's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Days Payable Chart

Ocugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Ocugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ocugen's Days Payable

For the Biotechnology subindustry, Ocugen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Days Payable distribution charts can be found below:

* The bar in red indicates where Ocugen's Days Payable falls into.

Ocugen Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ocugen's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (8.062	+	3.172)	/	2 )	/	0	*	365
=	5.617					/	0	*	365
=	N/A

Ocugen's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2.921	+	3.172)	/	2 )	/	0	*	365 / 4
=	3.0465					/	0	*	365 / 4
=	N/A

Ocugen Days Payable Related Terms

Thank you for viewing the detailed overview of Ocugen's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (Ocugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

OCGN:Mexico 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Executives

Junge Zhang	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu	officer: CFO/CBO	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri	director, officer: Chief Executive Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay	officer: Chief Scientific Officer	C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar	director	375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington	director	2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo	officer: CAO/SVP, Finance	C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian	officer: Chief Financial Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti	director	C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355